Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.4B Buy
12,317,194
+223,171
+2% +$46.3M 0.04% 395
2026
Q1
$2.71B Sell
12,094,023
-254,629
-2% -$63.5M 0.05% 327
2025
Q4
$2.97B Buy
12,348,652
+70,686
+0.6% +$18.1M 0.05% 297
2025
Q3
$3.36B Sell
12,277,966
-162,268
-1% -$44.3M 0.06% 274
2025
Q2
$3.21B Sell
12,440,234
-251,780
-2% -$60.1M 0.06% 275
2025
Q1
$2.84B Buy
12,692,014
+80,481
+0.6% +$18.8M 0.06% 285
2024
Q4
$2.88B Buy
12,611,533
+696,843
+6% +$168M 0.06% 291
2024
Q3
$2.91B Buy
11,914,690
+222,729
+2% +$49.8M 0.06% 282
2024
Q2
$2.24B Sell
11,691,961
-502,574
-4% -$102M 0.05% 330
2024
Q1
$2.41B Sell
12,194,535
-53,645
-0.4% -$9.83M 0.06% 313
2023
Q4
$2.11B Buy
12,248,180
+148,581
+1% +$22.8M 0.05% 322
2023
Q3
$1.79B Sell
12,099,599
-136,993
-1% -$24.8M 0.05% 336
2023
Q2
$2.67B Sell
12,236,592
-900,870
-7% -$201M 0.07% 266
2023
Q1
$2.88B Sell
13,137,462
-52,117
-0.4% -$11.3M 0.08% 227
2022
Q4
$2.75B Sell
13,189,579
-164,148
-1% -$36.1M 0.09% 234
2022
Q3
$2.92B Buy
13,353,727
+16,602
+0.1% +$3.78M 0.1% 190
2022
Q2
$2.8B Sell
13,337,125
-22,590
-0.2% -$4.81M 0.09% 212
2022
Q1
$3.24B Buy
13,359,715
+310,980
+2% +$75.2M 0.09% 214
2021
Q4
$3.4B Buy
13,048,735
+360,161
+3% +$93.5M 0.09% 213
2021
Q3
$3.34B Buy
12,688,574
+28,718
+0.2% +$7.85M 0.09% 189
2021
Q2
$3.12B Sell
12,659,856
-750,918
-6% -$158M 0.09% 209
2021
Q1
$2.6B Sell
13,410,774
-110,754
-0.8% -$22.2M 0.08% 246
2020
Q4
$2.87B Buy
13,521,528
+240,047
+2% +$47.9M 0.09% 196
2020
Q3
$2.28B Buy
13,281,481
+77,643
+0.6% +$14.3M 0.08% 212
2020
Q2
$2.54B Buy
13,203,838
+859,377
+7% +$141M 0.1% 172
2020
Q1
$1.82B Buy
12,344,461
+316,327
+3% +$50.4M 0.09% 201
2019
Q4
$1.86B Sell
12,028,134
-43,994
-0.4% -$6.34M 0.07% 260
2019
Q3
$1.63B Buy
12,072,128
+362,937
+3% +$47.6M 0.07% 271
2019
Q2
$1.43B Sell
11,709,191
-271,225
-2% -$30M 0.06% 305
2019
Q1
$1.25B Buy
11,980,416
+216,173
+2% +$22.3M 0.06% 334
2018
Q4
$1.34B Buy
11,764,243
+583,831
+5% +$62.6M 0.07% 271
2018
Q3
$1.29B Buy
11,180,412
+226,612
+2% +$24.8M 0.06% 335
2018
Q2
$1.13B Sell
10,953,800
-233,625
-2% -$23.6M 0.05% 365
2018
Q1
$1.1B Buy
11,187,425
+43,363
+0.4% +$4.1M 0.05% 361
2017
Q4
$944M Buy
11,144,062
+23,017
+0.2% +$1.9M 0.04% 425
2017
Q3
$856M Sell
11,121,045
-3,119,032
-22% -$239M 0.04% 431
2017
Q2
$1.11B Buy
14,240,077
+904,939
+7% +$64.7M 0.06% 335
2017
Q1
$960M Buy
13,335,138
+13,094,421
+5,440% +$905M 0.05% 367
2016
Q4
$14.9M Buy
240,717
+20,809
+9% +$1.27M 0.02% 631
2016
Q3
$14.2M Buy
219,908
+5,191
+2% +$346K 0.02% 634
2016
Q2
$13.6M Buy
214,717
+26,510
+14% +$1.56M 0.02% 627
2016
Q1
$10.9M Buy
188,207
+36,971
+24% +$2.09M 0.02% 660
2015
Q4
$8.12M Buy
151,236
+42,404
+39% +$2.39M 0.01% 730
2015
Q3
$5.55M Buy
108,832
+4,560
+4% +$245K 0.01% 755
2015
Q2
$5.88M Sell
104,272
-21,489
-17% -$1.36M 0.01% 797
2015
Q1
$9.03M Sell
125,761
-14,794
-11% -$961K 0.01% 703
2014
Q4
$7.88M Buy
140,555
+70,273
+100% +$3.67M 0.01% 732
2014
Q3
$3.46M Sell
70,282
-2,489
-3% -$127K 0.01% 930
2014
Q2
$3.68M Sell
72,771
-1,834
-2% -$90.9K 0.01% 909
2014
Q1
$3.33M Sell
74,605
-2,413
-3% -$108K 0.01% 930
2013
Q4
$3.63M Buy
77,018
+2,947
+4% +$149K 0.01% 902
2013
Q3
$3.91M Buy
74,071
+2,589
+4% +$126K 0.01% 821
2013
Q2
$3.23M Buy
+71,482
New +$3.39M 0.01% 832

Other funds holding RMD

BlackRock's RMD Position: Q2 2026 in Review

BlackRock increased its ResMed (RMD) stake by 1.8% in Q2 2026, buying an estimated $46.3M and bringing the position to 12,317,194 shares worth $2.4B. The position accounts for 0.04% of the portfolio, ranked #395.

BlackRock first reported a position in RMD in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.4B in Q4 2021. 698 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • BlackRock held 12,317,194 shares of ResMed worth $2.4B as of Q2 2026.
  • BlackRock bought 223,171 ResMed shares in Q2 2026, an estimated $46.3M.
  • ResMed made up 0.04% of BlackRock's portfolio in Q2 2026, its #395 holding.
  • BlackRock first reported a position in ResMed in Q2 2013 and has held it in 53 quarters since.
  • BlackRock's ResMed position peaked at $3.4B in Q4 2021.
  • 698 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.